信立泰(002294.SZ)：泰卡西单抗注射液申报上市申请获受理

Group 1 - The core point of the article is that Sinopharm (002294.SZ) announced that its subsidiary, Sinopharm (Suzhou) Pharmaceutical Co., Ltd., has received acceptance for the market application of its self-developed Class 1 biological drug "Ticagrelor Injection" from the National Medical Products Administration [1] Group 2 - The drug is intended to be applied for the treatment of hypercholesterolemia and mixed dyslipidemia [1]